Shock, Septic Clinical Trial
Official title:
Adherence to Clinical Practice Guidelines and the Impact of Audit and Feedback in the Emergency Department
This study will develop and test an intervention given to emergency medicine providers to improve adherence to clinical practice guidelines (CPGs) for pneumonia and sepsis.
This study will be performed at Denver Health Medical Center, a 477-bed urban, safety-net,
acute-care hospital located in Denver, Colorado. The adult ED is staffed by board-certified
emergency physicians at all times. These physicians supervise the care of all patients being
managed by resident physicians, nurse practitioners, physician assistants, and medical
students. Approximately 430 patients are admitted to the hospital from the ED each year with
community-acquired pneumonia (CAP) and severe sepsis (SS).
Adherence to CPGs will be measured at the level of the attending emergency physician. All
employed, attending emergency physicians working clinically in the adult ED at Denver Health
Medical Center at the start of the study will be included.
The investigators will use a step-wedge design to randomize physicians into clusters.
Randomization of physicians into clusters and randomization of clusters to intervention
timing will occur one week prior to delivery of the intervention to cluster one. he
intervention will consist of monthly audit and feedback on adherence to CPGs for CAP and SS.
Once a cluster enters its first intervention month, all physicians in that cluster will
receive an email detailing their adherence to both CAP and SS CPG for every month since the
start of the study. Adherence to the entire CPG as well as each component of the CPG will be
provided. In addition, physicians will be shown the median prevalence of adherence for all
physicians as well as where their adherence ranks among their physician group. Lastly, in a
separate secure email, physicians will be given patient identifiers (i.e., name, MRN, date
of visit) for each patient that received non-adherent care and will be told which component
of care was not adherent to the respective CPG so that they can review the case themselves,
if desired.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03592693 -
Vitamin C, Hydrocortisone and Thiamine for Septic Shock
|
Phase 2 | |
Terminated |
NCT01639664 -
COMPACT 2 - COMbining Plasma-filtration and Adsorption Clinical Trial 2
|
N/A | |
Withdrawn |
NCT01601938 -
Selenium Replacement and Serum Selenium Level in Severe Sepsis and Septic Shock Patients
|
Phase 2 | |
Recruiting |
NCT00335907 -
Protocol-driven Hemodynamic Support for Patients With Septic Shock
|
N/A | |
Completed |
NCT00000574 -
Ibuprofen in Sepsis Study
|
Phase 3 | |
Recruiting |
NCT04910841 -
Feasibility of Using the "CGM GUARDIAN 2" Interstitial Fluid Glucose Measurement System in Intensive Care Medicine
|
N/A | |
Active, not recruiting |
NCT04079829 -
Postoperative Respiratory Abnormalities
|
||
Recruiting |
NCT04569942 -
Australasian Resuscitation In Sepsis Evaluation: FLUid or Vasopressors In Emergency Department Sepsis
|
Phase 3 | |
Recruiting |
NCT04934943 -
"Mini Fluid Challenge Assessment: a Comparison Among Three Hemodynamic Tools"
|
||
Completed |
NCT01310790 -
Strategy of Early Improvement of Tissue Oxygenation Decrease the Mortality of Severe Sepsis and Septic Shock
|
Phase 4 | |
Completed |
NCT00241228 -
Haemofiltration Study : IVOIRE (hIgh VOlume in Intensive Care)
|
N/A | |
Completed |
NCT00046072 -
A Safety and Efficacy Study of Intravenous E5564 in Patients With Severe Sepsis
|
Phase 2 | |
Withdrawn |
NCT03122678 -
Thiamine Supplementation in Patients With Septic Shock
|
Phase 1 | |
Recruiting |
NCT06155812 -
Multimodal Vasopressor Strategy in Septic Shock
|
Phase 2/Phase 3 | |
Completed |
NCT04178148 -
Personalized Dose Optimization of Amikacin Guided by Pharmacokinetic Modeling Software in Patients With Septic Shock
|
N/A | |
Completed |
NCT01453270 -
Emergency Department Management of Sepsis Patients: A Goal-Oriented Non-Invasive Sepsis Trial
|
N/A | |
Completed |
NCT04576819 -
Role and Mechanisms of Lipid and Lipoprotein Dysregulation in Sepsis
|
||
Active, not recruiting |
NCT04055909 -
Efficacy, Safety and Tolerability of Nangibotide in Patients With Septic Shock
|
Phase 2 | |
Suspended |
NCT03193164 -
Neuromuscular Electrical Stimulation and Septic Shock
|
N/A | |
Completed |
NCT04647552 -
Effects of Hydrocortison Treatment on Angiotensin II and Angiotensin II Receptors in Patients With Septic Shock
|